137 related articles for article (PubMed ID: 30875344)
1. CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
Zhu Y; Zhang N; Ren D; Bi Y; Xu F; Niu W; Sun Q; Guo Z; Yuan R; Yuan F; Wu X; Cao Y; Yang F; Wang L; Du L; Li W; Xu Y; Li X; Zhu L; He L; Shi L; He G; Yu T
Clin Neuropharmacol; 2019; 42(2):32-36. PubMed ID: 30875344
[TBL] [Abstract][Full Text] [Related]
2. No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
Zhang N; Ji L; Chen Z; An L; Ren D; Bi Y; Guo Z; Yuan R; Yuan F; Dong Z; Yin L; Sun X; Yang F; Li X; Yu T; He L; Shi L; He G
Psychiatr Genet; 2020 Feb; 30(1):30-33. PubMed ID: 31842058
[TBL] [Abstract][Full Text] [Related]
3. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
Yeh YW; Chen CJ; Jang FL; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Shyu JF; Wan FJ; Lu RB; Huang SY
J Psychiatr Res; 2015 Feb; 61():33-9. PubMed ID: 25512257
[TBL] [Abstract][Full Text] [Related]
4. No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients.
Wu N; Liu L; Ren D; Yuan F; Bi Y; Guo Z; Hou B; Ji L; Han K; Feng M; Su K; Yu T; Li X; Yang F; Sun X; Dong Z; Yu S; Yi Z; Xu Y; He L; Wu S; Zhao L; Changqun C; Shi Y; He G
Clin Neuropharmacol; 2021 Mar-Apr 01; 44(2):53-56. PubMed ID: 33480616
[TBL] [Abstract][Full Text] [Related]
5. CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.
Lin KM; Tsou HH; Tsai IJ; Hsiao MC; Hsiao CF; Liu CY; Shen WW; Tang HS; Fang CK; Wu CS; Lu SC; Kuo HW; Liu SC; Chan HW; Hsu YT; Tian JN; Liu YL
Pharmacogenomics; 2010 Nov; 11(11):1535-43. PubMed ID: 21121774
[TBL] [Abstract][Full Text] [Related]
6. GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.
Sun Q; Yuan F; Yuan R; Ren D; Zhu Y; Bi Y; Hu J; Guo Z; Xu F; Niu W; Ma G; Wu X; Yang F; Wang L; Li X; Yu T; He L; He G
Medicine (Baltimore); 2019 May; 98(19):e15456. PubMed ID: 31083176
[TBL] [Abstract][Full Text] [Related]
7. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients.
Zou YF; Wang Y; Liu P; Feng XL; Wang BY; Zang TH; Yu X; Wei J; Liu ZC; Liu Y; Tao M; Li HC; Li KQ; Hu J; Li M; Zhang KR; Ye DQ; Xu XP
Neuropsychobiology; 2010; 61(2):71-8. PubMed ID: 20016225
[TBL] [Abstract][Full Text] [Related]
8. A novel NR3C2 polymorphism and the increased thyroid-stimulating hormone concentration are associated with venlafaxine treatment outcome in Chinese Han MDD patients.
Yuan F; Yuan R; Ren D; Bi Y; Niu W; Guo Z; Wu X; Xu F; Sun Q; Ma G; Yang F; Zhu Y; Yu T; Li X; He L; Shi L; He G
Psychiatry Res; 2020 Feb; 284():112690. PubMed ID: 31757642
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
Ng C; Sarris J; Singh A; Bousman C; Byron K; Peh LH; Smith DJ; Tan CH; Schweitzer I
Hum Psychopharmacol; 2013 Sep; 28(5):516-22. PubMed ID: 24014145
[TBL] [Abstract][Full Text] [Related]
10. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
[TBL] [Abstract][Full Text] [Related]
11. Psychomotor depressive symptoms may differentially respond to venlafaxine.
Singh AB; Bousman CA; Ng CH; Byron K; Berk M
Int Clin Psychopharmacol; 2013 May; 28(3):121-6. PubMed ID: 23442739
[TBL] [Abstract][Full Text] [Related]
12. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.
Wang P; Lv Q; Mao Y; Zhang C; Bao C; Sun H; Chen H; Yi Z; Cai W; Fang Y
J Affect Disord; 2018 Mar; 228():222-228. PubMed ID: 29275155
[TBL] [Abstract][Full Text] [Related]
13. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
14. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
[TBL] [Abstract][Full Text] [Related]
15. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776
[TBL] [Abstract][Full Text] [Related]
16. Harm avoidance involved in mediating the association between nerve growth factor (NGF) gene polymorphisms and antidepressant efficacy in patients with major depressive disorder.
Yeh YW; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Chen TY; Shyu JF; Wan FJ; Lu RB; Huang SY
J Affect Disord; 2015 Sep; 183():187-94. PubMed ID: 26021968
[TBL] [Abstract][Full Text] [Related]
17. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
Marshe VS; Maciukiewicz M; Rej S; Tiwari AK; Sibille E; Blumberger DM; Karp JF; Lenze EJ; Reynolds CF; Kennedy JL; Mulsant BH; Müller DJ
Am J Psychiatry; 2017 May; 174(5):468-475. PubMed ID: 28068779
[TBL] [Abstract][Full Text] [Related]
18. Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis.
Kato M; Asami Y; Wajsbrot DB; Wang X; Boucher M; Prieto R; Pappadopulos E
J Psychiatr Res; 2020 Oct; 129():160-167. PubMed ID: 32912597
[TBL] [Abstract][Full Text] [Related]
19. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
Wang HC; Yeh TL; Chang HH; Gean PW; Chi MH; Yang YK; Lu RB; Chen PS
Psychopharmacology (Berl); 2011 Feb; 213(4):773-9. PubMed ID: 20945066
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
